tiprankstipranks
Advertisement
Advertisement

KYTX Stock Latest News

Kyverna Therapeutics: Buy Rating Reiterated as Pipeline Progress and Strong Financial Runway Support Unchanged $25 Price Target
RatingsKyverna Therapeutics: Buy Rating Reiterated as Pipeline Progress and Strong Financial Runway Support Unchanged $25 Price Target
6d ago
KYTX
Kyverna Therapeutics reports Q2 EPS (63c), consensus (68c)
PremiumThe Fly
Kyverna Therapeutics reports Q2 EPS (63c), consensus (68c)
6d ago
KYTX
Kyverna: Buy Rating Reaffirmed as Manufacturing Deal De‑Risks Launch Path; $33 Price Target Maintained
PremiumRatings
Kyverna: Buy Rating Reaffirmed as Manufacturing Deal De‑Risks Launch Path; $33 Price Target Maintained
21d ago
KYTX
Kyverna secures long-term miv-cel manufacturing partnership
PremiumCompany Announcements
Kyverna secures long-term miv-cel manufacturing partnership
21d ago
8K
KYTX
Kyverna Therapeutics, ElevateBio announce miv-cel manufacturing agreement
PremiumThe Fly
Kyverna Therapeutics, ElevateBio announce miv-cel manufacturing agreement
21d ago
KYTX
Kyverna’s KYSA-8 Trial Completion Puts Autoimmune Cell Therapy in Investor Focus
PremiumCompany AnnouncementsKyverna’s KYSA-8 Trial Completion Puts Autoimmune Cell Therapy in Investor Focus
24d ago
KYTX
Cue Biopharma appoints Dominic Borie as chief medical officer
Premium
The Fly
Cue Biopharma appoints Dominic Borie as chief medical officer
1M ago
CUE
KYTX
Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed
Premium
The Fly
Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed
1M ago
KYTX
VERA
Kyverna Therapeutics Amends Term Loan, Extends Capital Access
PremiumCompany Announcements
Kyverna Therapeutics Amends Term Loan, Extends Capital Access
1M ago
8K
KYTX
Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer
PremiumThe Fly
Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer
2M ago
KYTX
Kyverna Therapeutics: Buy Rating Reaffirmed on Strong Miv-cel RA Data and Regulatory Momentum; $33 Price Target Unchanged
PremiumRatings
Kyverna Therapeutics: Buy Rating Reaffirmed on Strong Miv-cel RA Data and Regulatory Momentum; $33 Price Target Unchanged
2M ago
KYTX
Sami Corwin Initiates Buy on Kyverna (KYTX) on Differentiated miv-cel Efficacy and Advancing BLA for First Autoimmune CAR T Approval
PremiumRatings
Sami Corwin Initiates Buy on Kyverna (KYTX) on Differentiated miv-cel Efficacy and Advancing BLA for First Autoimmune CAR T Approval
3M ago
KYTX
Kyverna: Buy Rating Reiterated as Emerging Clinical Profile Supports $25 Unchanged Price Target
PremiumRatingsKyverna: Buy Rating Reiterated as Emerging Clinical Profile Supports $25 Unchanged Price Target
3M ago
KYTX
Kyverna Therapeutics presents updated COMPARE trial data at EULAR
Premium
The Fly
Kyverna Therapeutics presents updated COMPARE trial data at EULAR
3M ago
KYTX
Kyverna Therapeutics Stockholders Approve Directors and Auditor
Premium
Company Announcements
Kyverna Therapeutics Stockholders Approve Directors and Auditor
3M ago
8K
KYTX
Kyverna Therapeutics Names Gregory Martini as New CFO
PremiumCompany Announcements
Kyverna Therapeutics Names Gregory Martini as New CFO
3M ago
8K
KYTX
Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed
PremiumThe Fly
Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed
3M ago
IRWD
KYTX
Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright
PremiumThe Fly
Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright
3M ago
KYTX
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
PremiumThe Fly
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
3M ago
KYTX
Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
PremiumThe FlyKyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
3M ago
KYTX
Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
Premium
The Fly
Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
4M ago
KYTX
OMER
Kyverna Therapeutics Appoints Chief Commercial Officer for Growth
Premium
Company Announcements
Kyverna Therapeutics Appoints Chief Commercial Officer for Growth
4M ago
8K
KYTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >